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Cancer affects one in every 500 children younger 
than 15 years in the UK, and around 1800 new cases 
are diagnosed in this population every year.1 Despite 
advances in treatments and improved overall survival, 
children with cancer have a high symptom burden, 
related both to the underlying cancer and associated 
treatments that can substantially affect their physical, 
mental, social, and emotional wellbeing, and cognitive 
function.2 Moreover, there are major psychosocial 
and financial implications for families of children with 
cancer, and substantial societal health-care costs.
Effective symptom management is the cornerstone 
of high-quality oncology care. Lack of recognition 
of the child’s symptoms is likely to cause or worsen 
complications, delay alleviation of their symptoms, limit 
the ability to safely and effectively deliver treatments, 
increase hospital and emergency visits, and have a 
negative effect on clinical outcomes.3 Studies have 
shown that clinicians’ and parents’ perceptions of a 
child’s symptoms do not accurately reflect the child’s 
perspective, particularly for subjective attributes such as 
emotion, pain, cognition, and confidence for the future.4 
This incongruence is especially important for common, 
unobservable symptoms such as nausea, which can 
only be detected through self-reporting. Eliciting the 
patient’s voice through self-reporting of symptoms is 
crucial to optimising symptom management.
The importance of patient-centred care in improving 
the quality and effectiveness of health care is well 
recognised. One way to assess the effect of disease and 
treatment on symptoms is with the use of patient-
reported outcome measures. As stated by the US 
Food and Drug Administration, patient-reported 
outcome measures show “the status of a patient’s 
health condition that comes directly from the patient, 
without interpretation of the patient’s response by a 
clinician or anyone else”.5 A 2018 systematic review6 
identified 38 patient-reported outcome measures used 
in paediatric oncology research, measuring a total of 
81 symptoms. Self-reporting of symptoms is feasible 
in the paediatric population because most patient-
reported outcome instruments are specifically designed 
for ages ranging from 8 years to 18 years, with varying 
recall periods ranging from immediate recall, to up to 
1 year. The feasibility of collecting symptom data at 
multiple timepoints in longitudinal studies supports 
the potential use of these instruments as clinical tools 
to monitor symptoms. Electronic reporting platforms 
have shown promising results for children with cancer, 
highlighting the need for further development.7 
Communication of symptom data to clinical teams 
leads to improved parental understanding of the child’s 
symptoms, better communication with clinicians, 
and improvement of the children’s emotional health-
related quality of life.8 There is also evidence from an 
adult oncology setting that symptom reporting with 
automated clinician alerts results in better health-
related quality of life, fewer emergency room visits, 
fewer hospital admissions, longer duration of palliative 
chemotherapy, and improved survival compared with 
usual care.3
However, despite the availability of specific patient-
reported outcome symptom tools in paediatric 
oncology and evidence of clinical effectiveness when 
used in adult patient populations, their use in routine 
clinical paediatric oncology practice is minimal. An 
international survey9 revealed that 94% of health-care 
professionals working in paediatric oncology practices 
across 52 countries valued routine collection and 
use of patient-reported outcomes. However, several 
logistical issues, such as time constraints, insufficient 
staff, and financial limitations, were identified as 
potential barriers. Other key barriers were technological, 
which included a lack of standardised patient-reported 
outcome platforms that can interface with electronic 
health records, an absence of financial incentives 
to develop such platforms, as well as a shortage of 
standardised processes for integrating patient-reported 
outcomes in routine clinical workflow.10
There is a need to develop the infrastructure for 
systematic collection of symptom data that are 
communicated, in real time, to clinical teams to enable 
better identification and timely, efficient clinical 
management. Patient-reported outcome systems that 
assess quality of life, adverse effects, resource needs, 
and practical issues associated with treatment (such 
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as compliance to treatment) should be based on the 
needs of children, young people, and their families, 
be age appropriate, and easy for patients to use. They 
should also be clinically meaningful, actionable, and 
logistically practical from the clinical team’s perspective. 
The International Society for Quality of Life Research 
(ISOQoL) developed a user’s guide for implementing 
patient-reported outcome assessment in routine 
clinical practice, describing methodological and 
practical considerations. Successful implementation of 
such systems in routine clinical practice would require 
the engagement of everyone involved, including the 
patients and their families, treating clinical teams, 
hospital management, and funders, and would also 
require formal evaluation to assess the effectiveness of 
the system. Designing and co-producing standardised 
systems for symptom self-reporting in partnership with 
key stakeholders could improve the quality and safety of 
care, outcomes, and quality of life of children with cancer.
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Increasing access to next-generation sequencing in oncology 
for Brazil
A new generation of sequencing technologies has 
provided unprecedented opportunities for personalised 
medical care. In oncology, next-generation sequencing 
can be used to predict disease risk, determine primary 
tumour molecular alterations, and define resistance 
mechanisms to therapy. To fully achieve the benefits 
of next-generation sequencing in oncology, obstacles 
within the health-care system in which next-generation 
sequencing is implemented need to be overcome.
Brazil is the largest country in Latin America, with 
almost 210 million inhabitants, and it is estimated 
that cancer will become the leading cause of death in 
Brazil in 2028. Approximately 630 000 new cases are 
expected in 2018.1 Although all Brazilians are entitled 
For the ISOQoL user’s guide see 
http://www.isoqol.org/UserFiles/
file/UsersGuide.pdf
Downloaded for Stephen Yates (stephen.yates@uhb.nhs.uk) at University Hospitals Birmingham NHS Foundation Trust from ClinicalKey.com by Elsevier on April 21, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
